Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ ºÚÁÏÍø Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
ºÚÁÏÍø Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Mark Agulnik
Division of Hematology/Oncology
Feinberg School of Medicine
Northwestern University
USA
Mark Agulnik, MD, is Assistant Professor of medicine in the Division of Hematology and Oncology at Northwestern University in Chicago, IL.
Dr. Agulnik earned his medical degree at McGill University School of Medicine in Montreal, Canada. After graduating, he completed his residency in internal medicine at Dalhousie University in Halifax, Nova Scotia. His fellowship in hematology and oncology was conducted at the University of Illinois at Chicago. He subsequently completed a Clinical Research Fellowship at The University of Toronto’s Princess Margaret Hospital with a focus on Head and Neck Cancer.
Currently, Dr. Agulnik serves as Director of the Head and Neck and Sarcoma programs at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. He also serves as the Fellowship Program Director for the Department of Hematology and Oncology. Dr. Agulnik is a member of the American Society of Clinical Oncology, as well as the Connective Tissue Oncology Society. His research interests early drug development for both Head and Neck Cancers and Sarcomas. Dr. Agulnik is a panel member on both the National Comprehensive Cancer Network (NCCN) Bone Cancer Panel and Occult Primary Panel. He is a member of the National Cancer Institute Rare Tumors Task Force of the Head and Neck Cancer Steering Committee and an ECOG Head and Neck Cancer Committee Member.
His research interests early drug development for both Head and Neck Cancers,Salivary Gland Tumors, Thyroid Cancer and Sarcomas.
Make the best use of Scientific Research and information from our 700 + peer reviewed, ºÚÁÏÍø Journals